Clinical Trial Update: Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating the safety and efficacy of two regimens of intravitreal ranibizumab 0.5 mg in Chinese patients with neovascular age-related ma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Neovascular Age-related Macular Degeneration | Phase 4 | Status: UNKNOWN